Fractionated Stereotactic Radiotherapy (FSRT)

RADIATION3 trials

Sponsors

University Hospital Heidelberg, H. Lee Moffitt Cancer Center and Research Institute, Medical University of South Carolina

Conditions

Brain LesionsBrain MetastasesCancer (With CNS Involvement)Generalized Malignancy, PrimaryGlioma

Phase 1

Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

TerminatedNCT02187822

H. Lee Moffitt Cancer Center and Research InstituteBrain Lesions, Brain Metastases, Generalized Malignancy, Primary

Start: 2014-10-09End: 2018-03-31Updated: 2021-02-04

Phase 2

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

RecruitingNCT07227610

Medical University of South CarolinaBrain Metastases, Cancer (With CNS Involvement)

Start: 2026-02-03End: 2030-02-03Target: 54Updated: 2026-02-05

Unknown Phase

Carbon Ion Radiotherapy for Recurrent Gliomas

CompletedNCT01166308

University Hospital HeidelbergGlioma

Start: 2010-12-31End: 2016-04-30Updated: 2018-05-17

Related Papers

Carbon ion reirradiaton for patients with malignant gliomas: Toxicity and first results of the prospective dose-escalation phase I/II CINDERELLA trial.

Journal of Clinical Oncology2019-05-203 citations

ATNT-22A PHASE 1 STUDY OF TPI 287 CONCURRENT WITH FRACTIONATED STEREOTACTIC RADIOTHERAPY (FSRT) IN TREATMENT OF BRAIN METASTASES FROM ADVANCED BREAST AND NON-SMALL CELL LUNG (NSCL) CANCER

Neuro-Oncology2015-11-01

A phase I study of TPI 287 concurrent with fractionated stereotactic radiotherapy (FSRT) in treatment of brain metastases from advanced breast and non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2015-05-201 citations

Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial.

2010-10-0652 citations